The US FDA has issued a Complete Response Letter to Outlook Therapeutics (OTLK) for ONS-5010/Lytenava (bevacizumab-vikg)
https://seekingalpha.com/news/4536122-outlook-therapeutics-receives-crl--ressubmitted-bla--wet-amd-asset
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.